SCHEMBL9963407

SCHEMBL9963407

CC(C)N1C[C@@H](C)N(Cc2ccccn2)[C@@H](C)C1

nearest known ligand 0.54

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.45
HRH3 Q9Y5N1 3/20 0.42
KMT2A Q03164 2/20 0.39
CYP1A2 P05177 2/20 0.39
CYP2C19 P33261 2/20 0.39
ALDH1A1 P00352 2/20 0.39
MEN1 O00255 1/20 0.39
PKM P14618 1/20 0.39
CASP6 P55212 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
SIRT1 Q96EB6 1/20 0.38
CACNA1G O43497 1/20 0.37
CACNA1H O95180 1/20 0.37
CACNA1I Q9P0X4 1/20 0.37
DDB1 Q16531 1/20 0.37
CRBN Q96SW2 1/20 0.37
SIGMAR1 Q99720 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20149590 0.84 LMNA (0.41) LMNAKMT2ACYP1A2CYP2C19ALDH1A1
SCHEMBL9963410 0.84 OPRM1 (0.44) LMNAHRH3KMT2ACYP1A2CYP2C19
SCHEMBL9965979 0.83 LMNA (0.48) LMNAHRH3KMT2ACYP1A2CYP2C19
SCHEMBL12835921 0.82 LMNA (0.50) LMNAHRH3KMT2ACYP1A2CYP2C19
SCHEMBL9963401 0.82 LMNA (0.45) LMNAHRH3KMT2ACYP1A2CYP2C19
SCHEMBL9963404 0.82 LMNA (0.45) LMNAHRH3KMT2ACYP1A2CYP2C19
SCHEMBL9963126 0.79 LMNA (0.48) LMNAKMT2ACYP1A2CYP2C19ALDH1A1
SCHEMBL1088353 0.77 CASP6 (0.52) LMNAHRH3KMT2ACYP1A2CYP2C19
SCHEMBL20009000 0.76 KMT2A (0.44) HRH3KMT2AALDH1A1MEN1CACNA1G
SCHEMBL24780661 0.75 LMNA (0.39) LMNAHRH3CYP1A2CYP2C19ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8354403-B2 Pyrrolidine derived beta 3 adrenergic receptor agonists MERCK SHARP & DOHME CORP. (US) 2013-01-15 US disclosed
US-20120157432-A1 NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS MERCK SHARP & DOHME, CORP. (US) 2012-06-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120157432-A1 NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS ADRB3, ADRB1, ADRB2 LMNA 1824/4885HRH3 250/4885KMT2A 4265/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.